AbbVie(ABBV)
NORTH CHICAGO, IL
Pharmaceutical2 H-1B visas (FY2023)Focus: Small Molecules, Biologics
Error: Unreachable/Blocked
ImmunologyOncologyNeuroscienceAestheticsEye Care
Funding Stage
PUBLIC
Employees
50,000
Open Jobs
1495
Products & Portfolio (7)
43 discontinued products not shown
ACULAR
ketorolac tromethamine
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
postoperative inflammation in patients
1992
30
ACULAR LS
ketorolac tromethamine
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
ocular painburning/stinging following corneal refractive surgery
2003
15
ACUVAIL
ketorolac tromethamine
Peak
OPHTHALMIC · SOLUTION/DROPS
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
paininflammation following cataract surgery
2009
8
ALPHAGAN P
brimonidine tartrate
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertensionhypertension+1 more
2005
30
ALPHAGAN P
brimonidine tartrate
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertensionhypertension+1 more
2001
30
AVYCAZ
ceftazidime, avibactam
Peak
INTRAVENOUS · POWDER
[ see Clinical Pharmacology ( ) ].
the following infections caused by designated susceptible Gram-negative microorganisms in adultused in combination with metronidazole ( ) Complicated Urinary Tract Infections (cUTI)including Pyelonephritis ( ) Hospital-acquired Bacterial Pneumonia+19 more
2015
0
BETAGAN
levobunolol hydrochloride
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
CLINICAL PHARMACOLOGY Levobunolol hydrochloride is a noncardioselective beta-adrenoceptor blocking agent, equipotent at both beta 1 and beta 2 receptors. Levobunolol hydrochloride is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in its potential for direct myocardial depression. Accordingly, the levo isomer, levobunolol hydrochloride, is used. Levobunolol hydrochloride does not have significant local anesthetic (membrane-stabilizing) or intrinsic sympathomimetic activity. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function. Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous. Levobunolol hydrochloride ophthalmic solution, USP has been shown to be an active agent in lowering elevated as well as normal intraocular pressure (IOP) whether or not accompanied by glaucoma. Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. The onset of action with one drop of levobunolol hydrochloride ophthalmic solution can be detected within one hour after treatment, with maximum effect seen between 2 and 6 hours. A significant decrease in IOP can be maintained for up to 24 hours following a single dose. In controlled clinical studies of approximately two years duration, intraocular pressure was well-controlled in approximately 80% of subjects treated with levobunolol hydrochloride ophthalmic solution 0.5% twice a day. The mean IOP decrease from baseline was between 7 mm Hg and 8 mm Hg. No significant effects on pupil size, tear production or corneal sensitivity were observed. Levobunolol hydrochloride ophthalmic solution at the concentrations tested, when applied topically, decreased heart rate and blood pressure in some patients. The IOP-lowering effect of levobunolol hydrochloride ophthalmic solution was well maintained over the course of these studies. In a three-month clinical study, a single daily application of 0.5% levobunolol hydrochloride ophthalmic solution controlled the IOP of 72% of subjects achieving an overall mean decrease in IOP of 7.0 mm Hg. The primary mechanism of the ocular hypotensive action of levobunolol hydrochloride in reducing IOP is most likely a decrease in aqueous humor production. Levobunolol hydrochloride ophthalmic solution reduces IOP with little or no effect on pupil size or accommodation.
hypertensionglaucoma
1985
30
Pipeline & Clinical Trials
Paricalcitol
Secondary HyperparathyroidismClinical Trials (2)
NCT01939977Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.
Phase 4NCT04064827A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
Phase 3Long- and intermediate- acting insulins
DiabetesEffectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chron
Chronic Hepatitis CClinical Trials (1)
NCT02807402Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania
N/AEvaluating the Chain of Addiction Care (CAC)
Hepatitis C, ChronicThe Savella Pregnancy Registry
FibromyalgiaClinical Trials (1)
NCT01026077The Savella Pregnancy Registry
N/ASpecial Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Inve
PsoriasisClinical Trials (3)
NCT02985879A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
Phase 2NCT03413319Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
Phase 1NCT03744546Expanded Access to ABBV-8E12
N/AStudy to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lympho
Chronic Lymphocytic LeukemiaClinical Trials (1)
NCT03310190Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
N/AA Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Inel
Acute Myeloid Leukemia (AML)Clinical Trials (1)
NCT04253314A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation
N/ASpecial Investigation (Long-term Investigation) in Patients With Crohn's Disease
Crohn's DiseaseAdalimumab
Rheumatoid ArthritisClinical Trials (1)
NCT01768858Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
N/APhysical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical
Rheumatoid ArthritisA Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult
Heavy Menstrual BleedingClinical Trials (1)
NCT05026502A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
N/Azinc citrate 50 mg
Adjuvant Zinc May Increase the Efficacy of Botulinum ToxinClinical Trials (1)
NCT05894109Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids
N/ATreatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
Human Immunodeficiency Virus InfectionABBV-787
Acute Myeloid LeukemiaClinical Trials (1)
NCT06439966Expanded Access to ABBV-787
N/AStudy to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Partici
PsoriasisClinical Trials (1)
NCT04433442Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
N/AA Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Re
Acute Myeloid LeukemiaClinical Trials (1)
NCT05587049A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
N/AA Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Thera
Ankylosing Spondylitis (AS)Clinical Trials (1)
NCT03505892A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)
N/AA Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r)
HIV-1 InfectionClinical Trials (1)
NCT04138199A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation
N/AImpact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Pati
UveitisClinical Trials (1)
NCT03155243Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
N/AStudy to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (M
Multiple Myeloma (MM)Clinical Trials (1)
NCT04721002Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
N/AChronic Plaque Psoriasis (Ps) Registry
Chronic Plaque PsoriasisClinical Trials (1)
NCT00799877Chronic Plaque Psoriasis (Ps) Registry
N/ATavapadon
Parkinson DiseaseClinical Trials (5)
NCT04542499Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
Phase 3NCT04223193Flexible-Dose Trial in Early Parkinson's Disease (PD)
Phase 3NCT04201093Fixed-Dose Trial in Early Parkinson's Disease (PD)
Phase 3+2 more
Psycho-social CBT based training
Parkinson's DiseaseClinical Trials (1)
NCT02048605Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Patients With Parkinson's Disease
N/ASafety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthrit
Rheumatoid ArthritisSpecial Investigation in Patients With Crohn's Disease (All Patients Investigation)
Crohn's DiseaseAdalimumab
Rheumatoid ArthritisClinical Trials (1)
NCT02668640Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
N/ANo intervention.
Neovascular Age-Related Macular Degeneration (nAMD)Clinical Trials (1)
NCT05210803Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
N/Acaremessage
Medication AdherenceClinical Trials (1)
NCT03052231Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center
N/AAn Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotype
Hepatitis CClinical Trials (1)
NCT03740230An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
N/AVideocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis
PsoriasisClinical Trials (1)
NCT02162472Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis
N/AStudy to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adu
PsoriasisClinical Trials (1)
NCT04818385Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
N/AA Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalim
Crohn's DiseaseClinical Trials (1)
NCT02130362A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
N/AImmediate post-screening treatment education
HIVClinical Trials (1)
NCT01892228Pilot Study of Immediate HIV Treatment in Guangxi, China
N/AA Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adoles
Atopic DermatitisClinical Trials (1)
NCT05081557A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
N/AAssessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondyliti
Rheumatoid ArthritisAn Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adole
Atopic DermatitisClinical Trials (1)
NCT05669794An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World
N/AChama cha MamaToto
Pregnancy RelatedClinical Trials (1)
NCT03187873Chamas for Change Validation
N/AParitaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Obse
Chronic Hepatitis CClinical Trials (4)
NCT02615145Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
N/ANCT02798315Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study
N/ANCT02636608Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary
N/A+1 more
Videocapsule endoscopy
SpondyloarthropathyClinical Trials (1)
NCT03064815The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies
N/AA Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refracto
CancerClinical Trials (1)
NCT04198415A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
N/AGlecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotyp
Hepatitis C Virus (HCV)Clinical Trials (1)
NCT03341871Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
N/AA Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult
Acute Myeloid LeukemiaClinical Trials (2)
NCT06362031A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
N/ANCT05444972A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
N/AA Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chin
Atopic Dermatitis (AD)Clinical Trials (1)
NCT06503536A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review
N/AAdalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
PsoriasisClinical Trials (1)
NCT01320293Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
N/ASurveillance of Humira Injection in Korean Patients
Rheumatoid ArthritisReal World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribav
Chronic Hepatitis CClinical Trials (1)
NCT02640547Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C
N/AA Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Part
Rheumatoid Arthritis (RA)Clinical Trials (1)
NCT04574492A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
N/ADuodopa Home Titration Using Telemedicine: Evaluation of Use of Resources
Parkinson's DiseaseClinical Trials (1)
NCT01956032Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources
N/AOpen Jobs (1495)
Scientist I – Bioassay Sciences and Development (all genders) (full- or part-time, temporary for 2 years)
Ludwigshafen, RP
8h ago
Senior Account Executive
Mettawa, IL
8h ago
Director, Consumer CRM
Mettawa, IL
8h ago
Senior Scientist, Engineering I
North Chicago, IL
9h ago
Specialty Representative, Psychiatry - Hazard, KY
Remote
9h ago
Principal Research Scientist I, Biologics Analytical Research & Development
North Chicago, IL
9h ago
Associate Director, HCP Marketing - Parkinson's Disease
Mettawa, IL
9h ago
Senior Scientist I, Multi-specific Biologics
Worcester, MA
9h ago
Director, Brand Excellence - Pipeline
Mettawa, IL
10h ago
BTS Director (Hybrid)
Mettawa, IL
10h ago
Director, Strategic Planning & Operations, Value & Evidence
Mettawa, IL
10h ago
Engineer, Supplier Quality III (temp 6 months)
Heredia, Heredia Province
10h ago
MSL/Senior MSL, Dermatology - Tampa, Florida
Remote
10h ago
(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen
Remote
10h ago
Außendienstmitarbeiter Onkologie (all genders) für das Gebiet München, Landsberg, Garmisch-Patenkirchen, Rosenheim
Remote
10h ago
Sr. Professional Medical Representative
Remote
10h ago
Regulatory Affairs Manager(Immunology), Korea
Seoul, Seoul
10h ago
Senior Associate, RA TA Group, Regulatory Affairs (Specialty, Neurology, Eye Care)
Minato City, Tokyo
10h ago
Senior Director, Category Management and Procurement – Development (Clinical, Operations, Medical, Regulatory & HEOR)
North Chicago, IL
10h ago
District Manager, Hospital Surgical, Allergan Aesthetics, Florida
Remote
10h ago
Senior Manager, Talent Acquisition
Bengaluru, KA
10h ago
Senior Manager, Finance
Mettawa, IL
11h ago
Associate Director, RA Global Reg Strategy US & Canada
North Chicago, IL
11h ago
Program Lead II, Clinical Program Development
Irvine, CA
11h ago
Specialty Representative, Gastroenterology – Minneapolis, Minnesota
Remote
11h ago
Interview Prep Quick Facts
Portfolio: 329 approved products, 150 clinical trials
Top TAs: Oncology, Immunology, Neurology
H-1B (2023): 2 approvals
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 1495 active jobs
Portfolio Health
Pre-Launch74 (22%)
Launch1 (0%)
Growth3 (1%)
Peak42 (13%)
LOE Approaching167 (51%)
Post-LOE42 (13%)
329 total products
Therapeutic Area Focus
Oncology
10 marketed369 pipeline
Immunology
15 marketed216 pipeline
Neurology
36 marketed110 pipeline
Infectious Diseases
16 marketed123 pipeline
Ophthalmology
15 marketed34 pipeline
Women's Health
8 marketed25 pipeline
Gastroenterology
8 marketed24 pipeline
Cardiovascular
22 marketed9 pipeline
Marketed
Pipeline
Financials (FY2025)
Revenue
$54.3B6%
R&D Spend
$7.7B(14%)18%
Net Income
$4.9BCash
$5.5BHiring Trend
Actively Hiring
1495
Open Roles
+1744
Added
-132
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub